Results 2,681-2,700 of 4,002 for speaker:Rose Conway Walsh

Joint Oireachtas Committee on Agriculture, Food and the Marine: Implications of Brexit for Agriculture Sector: Discussion (Resumed) (20 Nov 2018)

Rose Conway Walsh: I thank Mr. Brennan for his presentation. What interaction has Bord Bia had with its British partners which play a similar role? Has it looked at how many transactions somebody who is exporting a single product might have to make after Brexit? In the event that there is a hard Brexit, at what tariffs could we be looking in the absence of an agreement on the customs union? Will the...

Joint Oireachtas Committee on Agriculture, Food and the Marine: Implications of Brexit for Agriculture Sector: Discussion (Resumed) (20 Nov 2018)

Rose Conway Walsh: I was referring to engagement in the context of opposing a hard Brexit and them using their influence similarly to organisations in the North. I took what Mr. Brennan said for granted because I know Bord Bia is active in engaging with them on a day-to-day basis.

Joint Oireachtas Committee on Agriculture, Food and the Marine: Implications of Brexit for Agriculture Sector: Discussion (Resumed) (20 Nov 2018)

Rose Conway Walsh: Has Bord Bia conducted stress tests on the companies that are exporting? How far down the supply chain will it go? What impact will it have on beef farmers, for example? Are they looking at a further price cut?

Joint Oireachtas Committee on Agriculture, Food and the Marine: Implications of Brexit for Agriculture Sector: Discussion (Resumed) (20 Nov 2018)

Rose Conway Walsh: How much is that out of?

Joint Oireachtas Committee on Agriculture, Food and the Marine: Implications of Brexit for Agriculture Sector: Discussion (Resumed) (20 Nov 2018)

Rose Conway Walsh: It is all spent.

Joint Oireachtas Committee on Agriculture, Food and the Marine: Implications of Brexit for Agriculture Sector: Discussion (Resumed) (20 Nov 2018)

Rose Conway Walsh: I would just like-----

Joint Oireachtas Committee on Agriculture, Food and the Marine: Implications of Brexit for Agriculture Sector: Discussion (Resumed) (20 Nov 2018)

Rose Conway Walsh: My question on transactions was not answered.

Joint Oireachtas Committee on Agriculture, Food and the Marine: Implications of Brexit for Agriculture Sector: Discussion (Resumed) (20 Nov 2018)

Rose Conway Walsh: I am trying to get a measure of the documentation and transactions. I do not want to take up anyone's time.

Joint Oireachtas Committee on Agriculture, Food and the Marine: Implications of Brexit for Agriculture Sector: Discussion (Resumed) (20 Nov 2018)

Rose Conway Walsh: I acknowledge that. Mr. Hamill has answered my question sufficiently, but Revenue told the Joint Committee on Finance, Public Expenditure and Reform, and Taoiseach several months ago that there could be up to 100 documents for each item. That would have serious repercussions.

Seanad: Order of Business (21 Nov 2018)

Rose Conway Walsh: I again wish to raise the matter of drugs that are used to treat rare diseases. There are two main issues here and the first is the lack of transparency within the current system.There is no way of finding out what cost-benefit analysis model is used for these drugs and what negative or positive externalities are used to make an assessment on whether the drugs will be approved. This process...

Seanad: Order of Business (21 Nov 2018)

Rose Conway Walsh: It is thanks to Deputy Pearse Doherty.

Seanad: Order of Business (21 Nov 2018)

Rose Conway Walsh: It confirms Fianna Fáil was asleep.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: I thank our guests for the work they do. I am following two drugs in particular, namely, Translarna and Spinraza. These drugs are what led me to the issue of rare diseases. I am not a permanent member of this committee. What has shocked me is the lack of transparency, which has been mentioned. Where there is no transparency, there is no trust. That is the real issue we need to tackle....

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: My time is limited because other witnesses are waiting outside. How long does it take, on average, for approval in Scotland?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: That is exactly what I am trying to get at. Is it due to a human blockage or lack of resources? What is it?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: It is obscure. Is Dr. Mitchell clear on the cost-benefit analysis that is used in the context of how many negative or positive externalities are taken into account or how the decision is arrived at? Is it long, short or medium term?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: That is the point. Is the EMA worth anything? Is it of any value at all or are its standards lower than the ones we have here? These treatments are often for children. Does a child in another country differ from one here? Why do we not take the EMA's decisions and say "Now we are here, what is the other part we need to get in order to get it approved in our country?" I cannot understand...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: That is right.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: I understand that.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: As Ms McGrath knows, in many of these cases, time is the one thing we do not have. I have significant issues with the cost because it is not negotiated. We are taking a headline cost and working out the cost-benefit analysis on that basis but we cannot hope to do so when the drug company is giving a cost expecting it to be negotiated, and rightly so - it would happen in any business...